Aidi Injection and Its Effects on Lung Cancer Cells
Author Information
Author(s): Zhang Jingyuan, Yang Siyun, Chen Xiaodong, Zhang Fanqin, Guo Siyu, Wu Chao, Wang Tieshan, Wang Haojia, Lu Shan, Qiao Chuanqi, Sheng Xiaoguang, Liu Shuqi, Zhang Xiaomeng, Wu Jiarui
Primary Institution: Beijing University of Chinese Medicine
Hypothesis
This study explores the molecular mechanism by which Aidi injection, when combined with gefitinib, attenuates gefitinib resistance in lung adenocarcinoma cells.
Conclusion
Aidi injection inhibits the migration and invasion of gefitinib-resistant lung adenocarcinoma cells by regulating the PLAT/FAK/AKT pathway.
Supporting Evidence
- ADI treatment alone and combined with gefitinib significantly inhibited the proliferation, migration, and invasion of PC9GR cells.
- Whole-transcriptome sequencing revealed that PLAT is a key target for the increased efficacy of ADI combined with gefitinib.
- ADI downregulates the expression of PLAT, TNC, ITGB3, p-AKT, p-PI3K, and p-FAK.
Takeaway
Aidi injection helps fight lung cancer by stopping cancer cells from moving and spreading, especially when used with another drug called gefitinib.
Methodology
In vitro and in vivo pharmacological experiments were conducted in PC9GR cells and NSG mice with PC9GR cell-derived tumors, using whole-transcriptome sequencing and bioinformatics methods.
Participant Demographics
Male NSG mice, approximately 20g, aged 5-8 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website